Despite these limitations, this study provides real-world evidence about the use of SGLT2 inhibitors and clinical outcomes in DM patients diagnosed with COVID-19, as well as valuable information in the current long COVID situation. The gene discussed is SLC5A2; the disease is COVID-19.